Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Voyager Therapeutics stock

Own Voyager Therapeutics stock in just a few minutes.

Voyager Therapeutics, Inc is a biotechnology business based in the US. Voyager Therapeutics shares (VYGR) are listed on the NASDAQ and all prices are listed in US Dollars. Voyager Therapeutics employs 177 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Voyager Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – VYGR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Voyager Therapeutics share price

Use our graph to track the performance of VYGR stocks over time.

Voyager Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$4.35 - $14.62
50-day moving average $5.08
200-day moving average $7.83
Wall St. target price$10.06
PE ratio 4.8061
Dividend yield N/A (0%)
Earnings per share (TTM) $0.98

Buy Voyager Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Voyager Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Voyager Therapeutics under- or over-valued?

Valuing Voyager Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Voyager Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Voyager Therapeutics's P/E ratio

Voyager Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Voyager Therapeutics shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Voyager Therapeutics's EBITDA

Voyager Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $31.2 million.

The EBITDA is a measure of a Voyager Therapeutics's overall financial performance and is widely used to measure a its profitability.

Voyager Therapeutics financials

Revenue TTM $171.1 million
Operating margin TTM 16%
Gross profit TTM $62.4 million
Return on assets TTM 5.55%
Return on equity TTM 28.95%
Profit margin 21.47%
Book value $4.13
Market capitalisation $180.7 million

TTM: trailing 12 months

Shorting Voyager Therapeutics shares

There are currently 2.2 million Voyager Therapeutics shares held short by investors – that's known as Voyager Therapeutics's "short interest". This figure is 9.6% up from 2.0 million last month.

There are a few different ways that this level of interest in shorting Voyager Therapeutics shares can be evaluated.

Voyager Therapeutics's "short interest ratio" (SIR)

Voyager Therapeutics's "short interest ratio" (SIR) is the quantity of Voyager Therapeutics shares currently shorted divided by the average quantity of Voyager Therapeutics shares traded daily (recently around 541852.47524752). Voyager Therapeutics's SIR currently stands at 4.04. In other words for every 100,000 Voyager Therapeutics shares traded daily on the market, roughly 4040 shares are currently held short.

However Voyager Therapeutics's short interest can also be evaluated against the total number of Voyager Therapeutics shares, or, against the total number of tradable Voyager Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Voyager Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Voyager Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.084% of the tradable shares (for every 100,000 tradable Voyager Therapeutics shares, roughly 84 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Voyager Therapeutics.

Find out more about how you can short Voyager Therapeutics stock.

Voyager Therapeutics share dividends

We're not expecting Voyager Therapeutics to pay a dividend over the next 12 months.

Voyager Therapeutics share price volatility

Over the last 12 months, Voyager Therapeutics's shares have ranged in value from as little as $4.35 up to $14.62. A popular way to gauge a stock's volatility is its "beta".

VYGR.US volatility(beta: 1.08)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Voyager Therapeutics's is 1.075. This would suggest that Voyager Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Voyager Therapeutics overview

Voyager Therapeutics, Inc. , a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc. , as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site